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Pierre Bougnères correctly points out the limitations of 
our genome-wide association study (GWAS) of variants 
affecting growth hormone (GH) response, all of which 
we raised in our “Discussion,” including a relatively small 
sample size for GWAS (1). Our main goal was to carry out 
the first genome-wide search powered to detect variants 
with moderate to large effects on GH response, and to test 
some specific hypotheses. Although our study size is small 
compared with most GWAS of polygenic traits, it was ad-
equately powered to detect larger effects that have been 
seen in other pharmacogenetic settings. Furthermore, the 
sample sizes needed for replication of individual variants 
that have themselves been proposed to have large effects, 
such as the GHRd3 variant, is much smaller than the 
study sizes needed for comprehensive GWAS discovery, 
for which effect sizes are more modest and appropriate 
correction for multiple testing is required. We were also 
well powered to test the hypothesis that genetically de-
termined height influences GH responsiveness, because 
we effectively examined a single hypothesis with large 
effect: A  single polygene score of 697 height-associated 
variants reflects the combined action of all 697 variants 
(explaining ~16% of the variance in height [2]).
In specific reference to the GHRd3 variant, although 
testing this variant was not the main goal of our study, our re-
sults still provide additional information on the likely strength 
of association with GH responsiveness. The meta-analysis 
cited by Bougnères (3), which encompassed 1680 children 
with a wide range of diagnoses and ancestries, reported a 
0.075 smaller change in height SD score after 1 year in chil-
dren who were homozygous for the more common (minor 
allele frequency ~0.72) wild-type (WT) allele, and a decrease 
of –0.159 in the subsample with GH deficiency. In our study, 
the SD of the change in height SD score was 0.4, meaning 
that the effect sizes of the WT allele reported in the meta-
analysis corresponds to a z score of –0.075/0.4 = –0.188 in all 
individuals and –0.159/0.4 = –0.40 in individuals with GH 
deficiency. These effect sizes correspond to approximately 
0.9% and approximately 4% of the variance in GH response 
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62% and 92% power to achieve a P value of less than .05 
in our sample of 614 children, of whom 276 had GH defi-
ciency. In our primary analysis, European-ancestry–only ana-
lysis, and European-ancestry GH deficiency–only analysis, 
we actually observed slight trends in the opposite direction 
(z scores of 0.024, 0.002, and 0.011, with P values of .66, 
.97, and .89, respectively). None of the 95% CIs around these 
z scores include the effect sizes reported in the meta-analysis, 
suggesting that the meta-analysis, at a minimum, has over-
estimated the effect of the GHRd3 variant.
Of note, in Wassenaar et al (3), the combined meta-analysis 
P values for association with 2 related measures of GH re-
sponsiveness ranged from .03 to .004, and the most signifi-
cant of these was driven largely by the study that first reported 
the association (4). We and others have previously noted that 
most candidate gene association studies that used a P value of 
less than .05 as a threshold for declaring significance turned 
out to be false positives (5-8), which is why the thresholds for 
declaring significance have since become much more strin-
gent (genome-wide significance, typically P less than 5 × 10–8 
[9]). We also note that if our study, with a total sample size of 
more than 600 individuals, were added to the meta-analysis in 
Wassenaar et al, the combined P value would move even fur-
ther away from this threshold of significance. To borrow the 
metaphor of David and Goliath from Bougnères, a few spe-
cial candidate gene association studies hit their target, but most 
turned out to have gone wide of the mark. Although we cannot 
definitively say that the association with GHRd3 and GH re-
sponsiveness is a false positive, our data strongly indicate that 
the effect size is not as large as has been previously suggested.
Finally, with respect to control of population substruc-
ture, we analyzed European-ancestry individuals separately 
and included principal components of ancestry in our ana-
lysis. The paper referenced by Bougnères (10) describes the 
effects of a subtle signal of population stratification on tests 
of selection that integrate information across genome-wide 
sets of summary association statistics for adult height; subtle 
residual stratification is unlikely to have affected the repli-
cation, or lack thereof, of individual variants in our study.
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